Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Science Officer

Chief Medical Officer

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-24	Premium	sold	Premium	Premium	Premium	-
2024-04-09	Premium	sold	Premium	Premium	Premium	-
2023-11-10	Premium	bought	Premium	Premium	Premium	-
2023-06-26	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-06-26	Premium	bought	Premium	Premium	Premium	-
2023-06-16	Premium	bought	Premium	Premium	Premium	-
2023-06-16	Premium	bought	Premium	Premium	Premium	-
2023-06-16	Premium	bought	Premium	Premium	Premium	-
2023-06-16	Premium	bought	Premium	Premium	Premium	-
2022-12-31	Premium	acquired	Premium	Premium	Premium	-
2022-11-14	Premium	acquired	Premium	Premium	Premium	-
2022-11-02	Premium	bought	Premium	Premium	Premium	-
2022-11-02	Premium	bought	Premium	Premium	Premium	-
2022-11-02	Premium	bought	Premium	Premium	Premium	-
2022-11-02	Premium	bought	Premium	Premium	Premium	-
2022-11-02	Premium	bought	Premium	Premium	Premium	-
2022-08-17	Premium	bought	Premium	Premium	Premium	-
2022-07-18	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-06-17	Premium	bought	Premium	Premium	Premium	-
2022-06-16	Premium	bought	Premium	Premium	Premium	-
2022-06-16	Premium	sold	Premium	Premium	Premium	Chief Science Officer
2022-06-15	Premium	bought	Premium	Premium	Premium	-
2022-06-15	Premium	bought	Premium	Premium	Premium	-
2022-06-14	Premium	bought	Premium	Premium	Premium	-

CLNN - Clene Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CLNN